Because there is an increase in circulating Type 1 T cells in psoriasis patients [3], we measured the effect of alefacept on circulating populations of Type 1 (IFN-γ-producing) and Type 2 (IL-4-producing) T cells by flow cytometry (Fig. 1). The gene discussed is IL4; the disease is psoriasis.